Cited by 1,649Epigenetics and DNA MethylationCancer Cells and MetastasisMechanisms of cancer metastasis

The DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.

EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells

Open access

Kleer, Celina G., Cao, Qi, Varambally, Sooryanarayana, Shen, Ronglai, Ota, Ichiro, Tomlins, Scott A., Ghosh, Debashis, Sewalt, Richard G. A. B., Otte, Arie P., Hayes, Daniel F., Sabel, Michael S., Livant, Donna, Weiss, Stephen J., Rubin, Mark A., Chinnaiyan, Arul M.·2003·Proceedings of the National Academy of Sciences

DOI 10.1073/pnas.1933744100PMC PMC208805

Open this paper in CoChat — free account

Abstract

The Polycomb Group Protein EZH2 is a transcriptional repressor involved in controlling cellular memory and has been linked to aggressive prostate cancer. Here we investigate the functional role of EZH2 in cancer cell invasion and breast cancer progression. EZH2 transcript and protein were consistently elevated in invasive breast carcinoma compared with normal breast epithelia. Tissue microarray analysis, which included 917 samples from 280 patients, demonstrated that EZH2 protein levels were strongly associated with breast cancer aggressiveness. Overexpression of EZH2 in immortalized human mammary epithelial cell lines promotes anchorage-independent growth and cell invasion. EZH2-mediated cell invasion required an intact SET domain and histone deacetylase activity. This study provides compelling evidence for a functional link between dysregulated cellular memory, transcriptional repression, and neoplastic transformation.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1073/pnas.1933744100

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The hallmarks of cancer
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Molecular portraits of human breast tumours
Perou, C., Sørlie, T., Eisen, M., van de Rijn, M., Jeffrey, S., Rees, C. A., Pollack, J., Ross, D., Johnsen, H., Akslen, L., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,551
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,239
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
Sørlie, T., Perou, C. M., Tibshirani, R. J., Aas, T., Geisler, S. B., Johnsen, H., Hastie, T. J., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 11,506
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536
Ki67 expression in breast cancer
Elkablawy, M. A., Albasri, A. M., Mohammed, R. A., Hussainy, A. S., Nouh, M. M., & Alhujaily, A. S. (2016) · Saudi Medical Journal · doi:10.15537/smj.2016.2.12285 · Cited by 4,382
Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing
Cao, R., Wang, L., Wang, H., Xia, L., Erdjument-Bromage, H., Tempst, P., Jones, R. S., & Zhang, Y. (2002) · Science · doi:10.1126/science.1076997 · Cited by 3,775
Cancer Statistics, 2003
Jemal, A., Murray, T., Samuels, A., Ghafoor, A., Ward, E., & Thun, M. J. (2003) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.53.1.5 · Cited by 3,275
The polycomb group protein EZH2 is involved in progression of prostate cancer
Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., Ghosh, D., Pienta, K. J., Sewalt, R. G. A. B., Otte, A. P., et al. (2002) · Nature · doi:10.1038/nature01075 · Cited by 2,717
Self-citation
Diseases of the Breast
Haagenson, C. (1971) · Cited by 1,773

Flagged first, then by citations

Show all 38 references

1 of the 38 references couldn’t be matched to a known paper.

Research works printed but not linked: 7

Ellis M. Hayes D. & Lippman M. (2000) in Diseases of the Breast eds. Harris J. Lippman M. E. & Morrow M. (Lippincott–Raven Philadelpha) pp. 749–798.
Clark G. M. (1996) in Diseases of the Breast eds. Harris. J. L. M.. Morrow M. & Hellman S. (Lippincott–Raven Philadephia) pp. 461–485.
Tie, F., Furuyama, T., Prasad-Sinha, J., Jane, E. & Harte, P. J. (2001) Development (Cambridge, U.K.) 128, 275–286.
Livant, D. L., Linn, S., Markwart, S. & Shuster, J. (1995) Cancer Res. 55, 5085–5093.7585556
Rhodes, D. R., Barrette, T. R., Rubin, M. A., Ghosh, D. & Chinnaiyan, A. M. (2002) Cancer Res. 62, 4427–4433.12154050
Gruvberger, S., Ringner, M., Chen, Y., Panavally, S., Saal, L. H., Borg, A., Ferno, M., Peterson, C. & Meltzer, P. S. (2001) Cancer Res. 61, 5979–5984.11507038
Livant, D. L., Brabec, R. K., Pienta, K. J., Allen, D. L., Kurachi, K., Markwart, S. & Upadhyaya, A. (2000) Cancer Res. 60, 309–320.10667582

Sorted by citations

Items 101–200 of 1,000

Polycomb-Mediated Loss of miR-31 Activates NIK-Dependent NF-κB Pathway in Adult T Cell Leukemia and Other Cancers
Yamagishi, M., Nakano, K., Miyake, A., Yamochi, T., Kagami, Y., Tsutsumi, A., Matsuda, Y., Sato‐Otsubo, A., Muto, S., Utsunomiya, A., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.12.015 · Cited by 331
BMI1 Sustains Human Glioblastoma Multiforme Stem Cell Renewal
Abdouh, M., Facchino, S., Chatoo, W., Balasingam, V., Ferreira, J., & Bernier, G. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.0968-09.2009 · Cited by 333
Inhibitors of Protein Methyltransferases and Demethylases
Kanıskan, H. Ü., Martini, M. L., & Jin, J. J. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00801 · Cited by 327
Loss of H3K27 trimethylation distinguishes malignant peripheral nerve sheath tumors from histologic mimics
Schaefer, I., Fletcher, C. D. �., & Hornick, J. L. (2015) · Modern Pathology · doi:10.1038/modpathol.2015.134 · Cited by 318
MicroRNA-26a Targets the Histone Methyltransferase Enhancer of Zeste homolog 2 during Myogenesis
Wong, C. F., & Tellam, R. L. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709614200 · Cited by 261
Expression Profiling of Serous Low Malignant Potential, Low-Grade, and High-Grade Tumors of the Ovary
Bonome, T., Lee, J.-Y., Park, D.-C., Radonovich, M., Pise-Masison, C. A., Brady, J. N., Gardner, G. J., Hao, K., Wong, W. H., Barrett, J. C., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2240 · Cited by 315
Histone methyltransferases in cancer
Albert, M., & Helin, K. (2009) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2009.10.007 · Cited by 320
Suz12 binds to silenced regions of the genome in a cell-type-specific mannerPreprint
Squazzo, S. L., O’Geen, H., Komashko, V., Krig, S. R., Jin, V. X., Jang, S.-W., Margueron, R., Reinberg, D., Green, R., & Farnham, P. (2006) · Genome Research · doi:10.1101/gr.5306606 · Cited by 324
Epigenetic and Chromatin Modifiers As Targeted Therapy of Hematologic Malignancies
Bhalla, K. N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.16.600 · Cited by 309
Histone onco-modifications
Füllgrabe, J., Kavanagh, E. T., & Joseph, B. (2011) · Oncogene · doi:10.1038/onc.2011.121 · Cited by 322
EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation
Richter, G. H. S., Plehm, S., Fasan, A., Rössler, S., Unland, R., Bennani-Baı̈ti, I. M., Hotfilder, M., Löwel, D., von Luettichau, I., Moßbrugger, I., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810759106 · Cited by 312
Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers
Wei, Y., Xia, W., Zhang, Z., Liu, J., Wang, H., Adsay, V. N., Albarracin, C. T., Yu, D., Abbruzzese, J. L., Mills, G. B., et al. (2008) · Molecular Carcinogenesis · doi:10.1002/mc.20413 · Cited by 311
Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance
Wilting, R. H., & Dannenberg, J. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.01.008 · Cited by 309
EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis
Velichutina, I., Shaknovich, R., Geng, H., Johnson, N. A., Gascoyne, R. D., Melnick, A. M., & Elemento, O. (2010) · Blood · doi:10.1182/blood-2010-04-280149 · Cited by 319
Cancer epigenetics: linking basic biology to clinical medicine
Tsai, H.-C., & Baylin, S. B. (2011) · Cell Research · doi:10.1038/cr.2011.24 · Cited by 303
Curcumin Analogue CDF Inhibits Pancreatic Tumor Growth by Switching on Suppressor microRNAs and Attenuating EZH2 Expression
Bao, B., Ali, S. S., Banerjee, S., Wang, Z., Logna, F., Azmi, A. S., Kong, D., Ahmad, A., Li, Y., Padhyé, S., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-2182 · Cited by 300
Low levels of miR‐92b/96 induce PRMT5 translation and H3R8/H4R3 methylation in mantle cell lymphoma
Pal, S., Baiocchi, R. A., Byrd, J. C., Grever, M. R., Jacob, S. T., & Sif, S. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601794 · Cited by 291
Silenced Tumor Suppressor Genes Reactivated by DNA Demethylation Do Not Return to a Fully Euchromatic Chromatin State
McGarvey, K. M., Fahrner, J. A., Greene, E., Martens, J. H. A., Jenuwein, T., & Baylin, S. B. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2481 · Cited by 285
Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2
Chen, D., Bohrer, L. R., Rai, A. N., Pan, Y., Gan, L., Zhou, X., Bagchi, A., Simon, J. A., & Huang, H. (2010) · Nature Cell Biology · doi:10.1038/ncb2116 · Cited by 292
Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapy
Hua, H., Kong, Q., Yin, J., Zhang, J. C., & Jiang, Y. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00904-3 · Cited by 287
Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer.
Collett, K., Eide, G. E., Arnes, J. B., Stefansson, I. M., Eide, J., Braaten, A. O., Aas, T., Otte, A. P., & Akslen, L. A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1533 · Cited by 272
Self-citation
Protein Arginine Methyltransferase 5 Suppresses the Transcription of the RB Family of Tumor Suppressors in Leukemia and Lymphoma Cells
Wang, L., Pal, S., & Sif, S. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00923-08 · Cited by 265
EZH2 Methyltransferase and H3K27 Methylation in Breast Cancer
Yoo, K. H., & Hennighausen, L. G. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.8.59 · Cited by 267
Long Noncoding RNAs in Cancer: From Function to Translation
Sahu, A., Singhal, U., & Chinnaiyan, A. M. (2015) · Trends in cancer · doi:10.1016/j.trecan.2015.08.010 · Cited by 262
Self-citation
Differential expression of selected histone modifier genes in human solid cancers
Özdağ, H., Teschendorff, A. E., Ahmed, A. A., Hyland, S. J., Blenkiron, C., Bobrow, L., Veerakumarasivam, A., Burtt, G. J., Subkhankulova, T., Arends, M. J., et al. (2006) · BMC Genomics · doi:10.1186/1471-2164-7-90 · Cited by 266
Targeting Epigenetics in Cancer
Bennett, R. L., & Licht, J. D. (2017) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-105106 · Cited by 254
EZH2 Generates a Methyl Degron that Is Recognized by the DCAF1/DDB1/CUL4 E3 Ubiquitin Ligase Complex
Lee, J. M., Lee, J. S., Kim, H.-K., Kim, K., Park, H., Kim, J.-Y., Lee, S. H., Kim, I. S., Kim, J., Lee, M., et al. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.09.004 · Cited by 268
Throwing the cancer switch: reciprocal roles of polycomb and trithorax proteins
Mills, A. A. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2931 · Cited by 256
Cancer genetics of epigenetic genes
Miremadi, A., Oestergaard, M. Z., Pharoah, P. D. P., & Caldas, C. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm021 · Cited by 255
Histone modification patterns and epigenetic codes
Lennartsson, A., & Ekwall, K. (2009) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2008.12.006 · Cited by 259
UTX and MLL4 Coordinately Regulate Transcriptional Programs for Cell Proliferation and Invasiveness in Breast Cancer Cells
Kim, J., Sharma, A., Dhar, S. S., Lee, S.-H., Gu, B., Chan, C., Lin, H., & Lee, M. G. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1896 · Cited by 249
EZH2-Targeted Therapies in Cancer: Hype or a Reality
Eich, M., Athar, M., Ferguson, J. E., & Varambally, S. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-2147 · Cited by 254
Self-citation
The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression
Niknafs, Y. S., Han, S., Ma, T., Speers, C. W., Zhang, C., Wilder-Romans, K., Iyer, M. K., Pitchiaya, S., Malik, R., Hosono, Y., et al. (2016) · Nature Communications · doi:10.1038/ncomms12791 · Cited by 246
Self-citation
Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease
Bhat, K. P., Kanıskan, H. Ü., Jin, J. J., & Gozani, O. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00108-x · Cited by 250
Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma
Sudo, T., Utsunomiya, T., Mimori, K., Nagahara, H., Ogawa, K., Inoue, H., Wakiyama, S., Fujita, H., Shirouzu, K., & Mori, M. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602531 · Cited by 245
Discovery of a first-in-class EZH2 selective degrader
Ma, A., Στρατικόπουλος, Η., Park, K., Wei, J., Martin, T. C., Yang, X., Schwarz, M. C., Leshchenko, V. V., Rialdi, A., Dale, B., et al. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0421-4 · Cited by 245
Down-regulation of Human DAB2IP Gene Expression Mediated by Polycomb Ezh2 Complex and Histone Deacetylase in Prostate Cancer
Chen, H., Tu, S.-W., & Hsieh, J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501379200 · Cited by 242
miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis
Smits, M., Nilsson, J. A., Mir, S. E., van der Stoop, P. M., Hulleman, E., Niers, J. M., Hamer, P. C. D. W., Márquez, V. E., Cloos, J. J., Krichevsky, A. M., et al. (2010) · Oncotarget · doi:10.18632/oncotarget.205 · Cited by 242
Evaluation of H istone 3 Lysine 27 Trimethylation ( H3K27me3 ) and Enhancer of Zest 2 ( EZH 2) in Pediatric Glial and Glioneuronal Tumors Shows Decreased H3K27me3 in H3F3A K27M Mutant Glioblastomas
Venneti, S., Garimella, M., Sullivan, L. M., Martínez, D., Huse, J. T., Heguy, A., Santi, M., Thompson, C. B., & Judkins, A. R. (2013) · Brain Pathology · doi:10.1111/bpa.12042 · Cited by 249
EZH2: biology, disease, and structure-based drug discovery
Tan, J., Yan, Y., Wang, X., Jiang, Y., & Xu, H. E. (2013) · Acta Pharmacologica Sinica · doi:10.1038/aps.2013.161 · Cited by 248
Histone deacetylase inhibitors: Multifunctional anticancer agents
Liu, T., Kuljaca, S., Tee, A. E., & Marshall, G. M. (2006) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2005.12.006 · Cited by 234
Polycomb Protein EZH2 Regulates Tumor Invasion via the Transcriptional Repression of the Metastasis Suppressor RKIP in Breast and Prostate Cancer
Ren, G., Baritaki, S., Marathe, H. G., Feng, J., Park, S., Beach, S., Bazeley, P. S., Beshir, A. B., Fenteany, G., Mehra, R., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3546 · Cited by 235
Pathologically decreased miR-26a antagonizes apoptosis and facilitates carcinogenesis by targeting MTDH and EZH2 in breast cancer
Zhang, B., Liu, X.-X., He, J.-R., Zhou, C., Guo, M., He, M., Li, M.-F., Chen, G., & Zhao, Q. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq209 · Cited by 228
Identification of ( R )- N -((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1 H -indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymphomas
Vaswani, R. G., Gehling, V. S., Dakin, L. A., Cook, A. S., Nasveschuk, C. G., Duplessis, M., Iyer, P., Balasubramanian, S., Zhao, F., Good, A. C., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01315 · Cited by 229
Genomic and Epigenomic Alterations in Cancer
Chakravarthi, B. V. S. K., Nepal, S., & Varambally, S. (2016) · American Journal Of Pathology · doi:10.1016/j.ajpath.2016.02.023 · Cited by 232
Self-citation
Integrative Genomics Analysis Reveals Silencing of β-Adrenergic Signaling by Polycomb in Prostate Cancer
Yu, J., Cao, Q., Mehra, R., Laxman, B., Yu, J., Tomlins, S. A., Creighton, C. J., Dhanasekaran, S. M., Shen, R., Chen, G., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.10.016 · Cited by 227
Self-citation
p63 Expression in Breast Cancer
Koker, M. M., & Kleer, C. G. (2004) · The American Journal of Surgical Pathology · doi:10.1097/01.pas.0000138183.97366.fd · Cited by 220
Self-citation
Subunit Contributions to Histone Methyltransferase Activities of Fly and Worm Polycomb Group Complexes
Ketel, C. S., Andersen, E., Vargas, M. L., Suh, J., Strome, S., & Simon, J. A. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.16.6857-6868.2005 · Cited by 238
Insights from transgenic mouse models of PyMT-induced breast cancer: recapitulating human breast cancer progression in vivo
Attalla, S. S., Taifour, T., Bui, T., & Muller, W. J. (2020) · Oncogene · doi:10.1038/s41388-020-01560-0 · Cited by 215
Cancer, metastasis, and the epigenome
Kiri, S., & Ryba, T. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02069-w · Cited by 228
Role of the Polycomb Repressive Complex 2 (PRC2) in Transcriptional Regulation and CancerPreprint
Laugesen, A., Højfeldt, J. W., & Helin, K. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026575 · Cited by 225
Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer
Matsukawa, Y., Semba, S., Kato, H., Ito, A., Yanagihara, K., & Yokozaki, H. (2006) · Cancer Science · doi:10.1111/j.1349-7006.2006.00203.x · Cited by 215
DNA Microarrays Reveal Relationship of Ewing Family Tumors to Both Endothelial and Fetal Neural Crest-Derived Cells and Define Novel Targets
Staege, M. S., Hutter, C., Neumann, I., Foja, S., Hattenhorst, U. E., Hansen, G., Afar, D., & Burdach, S. E. G. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-4059 · Cited by 217
EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes β-Catenin–Dependent Hepatocarcinogenesis
Cheng, A. S. L., Lau, S. S., Chen, Y., Kondo, Y., Li, M. S. M., Feng, H., Ching, A. K.-K., Cheung, K. F., Wong, H. K., TONG, J. H. M., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3342 · Cited by 212
Concise Review: Roles of Polycomb Group Proteins in Development and Disease: A Stem Cell Perspective
Rajasekhar, V. K., & Begemann, M. (2007) · Stem Cells · doi:10.1634/stemcells.2006-0608 · Cited by 210
Coordinated Regulation of Polycomb Group Complexes through microRNAs in Cancer
Cao, Q., Mani, R. S., Ateeq, B., Dhanasekaran, S. M., Asangani, I. A., Prensner, J. R., Kim, J. H., Brenner, J. C., Jing, X., Cao, X., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.016 · Cited by 208
Self-citation
Epigenetic silencing of tumor suppressor genes: Paradigms, puzzles, and potential
Kazanets, A., Shorstova, T., Hilmi, K., Marques, M., & Witcher, M. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.04.001 · Cited by 203
Methylation of EZH2 by PRMT1 regulates its stability and promotes breast cancer metastasis
Li, Z., Wang, D., Lü, J., Huang, B., Wang, Y., Dong, M., Fan, D., Li, H., Gao, Y., Hou, P., et al. (2020) · Cell Death and Differentiation · doi:10.1038/s41418-020-00615-9 · Cited by 198
Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1
Gonzalez, M. E., Li, X., Toy, K. A., DuPrie, M. L., Ventura, A. C., Banerjee, M., Ljungman, M. E., Merajver, S. D., & Kleer, C. G. (2008) · Oncogene · doi:10.1038/onc.2008.433 · Cited by 201
Self-citation
The winding path of protein methylation research: milestones and new frontiers
Murn, J., & Shi, Y. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.35 · Cited by 205
Increased Expression of the Polycomb Group Gene, EZH2, in Transitional Cell Carcinoma of the Bladder
Raman, J. D., Mongan, N. P., Tickoo, S. K., Boorjian, S. A., Scherr, D. S., & Gudas, L. J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1047 · Cited by 197
Enhancer of Zeste Homologue 2 (EZH2) Down-regulates RUNX3 by Increasing Histone H3 Methylation
Fujii, S., Ito, K., Ito, Y., & Ochiai, A. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m800224200 · Cited by 199
EZH2-Dependent Suppression of a Cellular Senescence Phenotype in Melanoma Cells by Inhibition of p21/ CDKN1A Expression
Fan, T., Jiang, S., Chung, N., Alikhan, A., Ni, C., Lee, C. R., & Hornyak, T. J. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0511 · Cited by 199
Activated p53 suppresses the histone methyltransferase EZH2 gene
Tang, X., Milyavsky, M., Shats, I., Erez, N., Goldfinger, N., & Rotter, V. (2004) · Oncogene · doi:10.1038/sj.onc.1207706 · Cited by 193
Epi-drugs to fight cancer: From chemistry to cancer treatment, the road ahead
Mai, A., & Altucci, L. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.08.020 · Cited by 192
Regulation of Pancreatic Tumor Cell Proliferation and Chemoresistance by the Histone Methyltransferase Enhancer of Zeste Homologue 2
Ougolkov, A. V., Bilim, V. N., & Billadeau, D. D. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1013 · Cited by 197
Epigenetic modulation of the miR-200 family is associated with transition to a breast cancer stem cell-like state
Lim, Y., Wright, J. A., Attema, J. L., Gregory, P. A., Bert, A. G., Smith, E., Thomas, D., Drew, P. A., Khew‐Goodall, Y., & Goodall, G. J. (2013) · Journal of Cell Science · doi:10.1242/jcs.122275 · Cited by 199
Bypass of senescence by the polycomb group protein CBX8 through direct binding to the INK4A‐ARF locus
Dietrich, N., Bracken, A. P., Trinh, E., Schjerling, C. K., Koseki, H., Rappsilber, J., Helin, K., & Hansen, K. H. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601632 · Cited by 187
Targeting histone lysine methylation in cancer
McGrath, J. P., & Trojer, P. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.01.002 · Cited by 190
Epigenetic Changes in Cancer
Iacobuzio–Donahue, C. A. (2008) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev.pathol.3.121806.151442 · Cited by 188
Epigenetic alteration and microRNA dysregulation in cancer
Suzuki, H., Maruyama, R., Yamamoto, E., & Kai, M. (2013) · Frontiers in Genetics · doi:10.3389/fgene.2013.00258 · Cited by 194
Genomic analysis of estrogen cascade reveals histone variant H2A.Z associated with breast cancer progression
Hua, S., Kallen, C. B., Dhar, R., Baquero, M. T., Mason, C. E., Russell, B. A., Shah, P. K., Liu, J., Khramtsov, A., Tretiakova, M., et al. (2008) · Molecular Systems Biology · doi:10.1038/msb.2008.25 · Cited by 192
Enhancer of Zeste Homolog 2 Inhibition Attenuates Renal Fibrosis by Maintaining Smad7 and Phosphatase and Tensin Homolog Expression
Zhou, X., Zang, X., Ponnusamy, M., Masucci, M. V., Tolbert, E. M., Gong, R., Zhao, T. C., Liu, N., Bayliss, G. P., Dworkin, L. D., et al. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015040457 · Cited by 191
Comprehensive analysis of long non-coding RNAs in human breast cancer clinical subtypes
Su, X., Malouf, G. G., Chen, Y., Zhang, J., Yao, H., Valero, V., Weinstein, J. N., Spano, J., Meric‐Bernstam, F., Khayat, D., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2454 · Cited by 186
DNMT1 and EZH2 mediated methylation silences the microRNA-200b/a/429 gene and promotes tumor progression
Ning, X., Shi, Z., Liu, X., Zhang, A., Han, L., Jiang, K., Kang, C., & Zhang, Q. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.01.005 · Cited by 189
EZH2 inhibitor GSK126 suppresses antitumor immunity by driving production of myeloid-derived suppressor cells
Huang, S., Wang, Z., Zhou, J., Huang, J., Zhou, L., Luo, J., Wan, Y. Y., Long, H., & Zhu, B. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2395 · Cited by 185
EZH2 expands breast stem cells through activation of NOTCH1 signaling
Gonzalez, M. E., Moore, H. M., Li, X., Toy, K. A., Huang, W., Sabel, M. S., Kidwell, K., & Kleer, C. G. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1308953111 · Cited by 198
Self-citation
Gene Alterations Identified by Expression Profiling in Tumor-Associated Endothelial Cells from Invasive Ovarian Carcinoma
Lü, C., Bonome, T., Li, Y., Kamat, A. A., Han, L. Y., Schmandt, R. E., Coleman, R. L., Gershenson, D. M., Jaffe, R. B., Birrer, M. J., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3700 · Cited by 186
Recent developments in epigenetic cancer therapeutics: clinical advancement and emerging trends
Nepali, K., & Liou, J. (2021) · Journal of Biomedical Science · doi:10.1186/s12929-021-00721-x · Cited by 187
Driver mutations of cancer epigenomes
Roy, D. M., Walsh, L. A., & Chan, T. A.-T. (2014) · Protein & Cell · doi:10.1007/s13238-014-0031-6 · Cited by 188
Epigenomics and Breast Cancer
Lo, P., & Sukumar, S. V. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.12.1879 · Cited by 191
Polycomb-Group Oncogenes EZH2, BMI1, and RING1 Are Overexpressed in Prostate Cancer With Adverse Pathologic and Clinical Features
van Leenders, G. J. L. H., Dukers, D. F., Hessels, D., van den Kieboom, S. W. M., Hulsbergen, C., Witjes, J. A., Otte, A. P., Meijer, C. J. L. M., & Raaphorst, F. M. (2006) · European Urology · doi:10.1016/j.eururo.2006.11.020 · Cited by 186
Self-citation
Myc Enforces Overexpression ofEZH2in Early Prostatic Neoplasia via Transcriptional and Post-transcriptional Mechanisms
Koh, C. M., Iwata, T., Zheng, Q., Bethel, C. R., Yegnasubramanian, S., & Marzo, A. M. D. (2011) · Oncotarget · doi:10.18632/oncotarget.327 · Cited by 188
KDM2B promotes pancreatic cancer via Polycomb-dependent and -independent transcriptional programs
Tzatsos, A., Paskaleva, P., Ferrari, F., Deshpande, V., Stoykova, S., Contino, G., Wong, K., Lan, F., Trojer, P., Park, P. J., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64535 · Cited by 178
PRC2 overexpression and PRC2-target gene repression relating to poorer prognosis in small cell lung cancer
Sato, T., Kaneda, A., Tsuji, S., Isagawa, T., Yamamoto, S., Fujita, T., Yamanaka, R., Tanaka, Y., Nukiwa, T., Márquez, V. E., et al. (2013) · Scientific Reports · doi:10.1038/srep01911 · Cited by 181
Genetic alterations of histone lysine methyltransferases and their significance in breast cancer
Liu, L., Kimball, S., Liu, H., Holowatyj, A., & Yang, Z.-Q. (2014) · Oncotarget · doi:10.18632/oncotarget.2967 · Cited by 178
EZH2 in normal and malignant hematopoiesis
Lund, K., Adams, P. D., & Copland, M. (2013) · Leukemia · doi:10.1038/leu.2013.288 · Cited by 181
EZH2 Mediates Epigenetic Silencing of Neuroblastoma Suppressor Genes CASZ1 , CLU , RUNX3 , and NGFR
Wang, C., Liu, Z., Woo, C., Li, Z., Wang, L., Wei, J. S., Márquez, V. E., Bates, S. E., Jin, Q., Khan, J. I., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0961 · Cited by 178
MicroRNA-101 Exerts Tumor-Suppressive Functions in Non-small Cell Lung Cancer through Directly Targeting Enhancer of Zeste Homolog 2
Zhang, J., Guo, J., Liu, D., Liu, Q., & Wang, J. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318208eb35 · Cited by 173
DNA Methylation and Cancer
Taberlay, P. C., & Jones, P. A. (2010) · Springer eBooks · doi:10.1007/978-3-7643-8989-5_1 · Cited by 174
Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials
Niu, Z., Jin, R., Zhang, Y., & Li, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01200-x · Cited by 185
Histone Demethylase KDM6B Promotes Epithelial-Mesenchymal Transition
Ramadoss, S., Chen, X., & Wang, C. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.424903 · Cited by 171
Histone Modifiers in Cancer: Friends or Foes?
Cohen, I., Poręba, E., Kamieniarz-Gdula, K., & Schneider, R. (2011) · Genes & Cancer · doi:10.1177/1947601911417176 · Cited by 176
Key molecular mechanisms in lung cancer invasion and metastasis: A comprehensive review
Perlikos, F., Harrington, K. J., & Syrigos, K. N. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.12.007 · Cited by 174
ANCCA/ATAD2 Overexpression Identifies Breast Cancer Patients with Poor Prognosis, Acting to Drive Proliferation and Survival of Triple-Negative Cells through Control of B-Myb and EZH2
Kalashnikova, E. V., Revenko, A. S., Gemo, A. T., Andrews, N. P., Tepper, C. G., Zou, J. X., Cardiff, R. D., Borowsky, A. D., & Chen, H.-W. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1199 · Cited by 173
The emerging role of PI3K/AKT-mediated epigenetic regulation in cancer
Spangle, J. M., Roberts, T. M., & Zhao, J. J. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.03.002 · Cited by 170
The central role of EED in the orchestration of polycomb group complexes
Cao, Q., Wang, X., Zhao, M., Yang, R., Malik, R., Qiao, Y., Poliakov, A., Yocum, A. K., Li, Y., Chen, W., et al. (2014) · Nature Communications · doi:10.1038/ncomms4127 · Cited by 178
Self-citation
Epigenetics of hematopoiesis and hematological malignanciesPreprint
Hu, D., & Shilatifard, A. (2016) · Genes & Development · doi:10.1101/gad.284109.116 · Cited by 175
Mining for regulatory programs in the cancer transcriptome
Rhodes, D. R., Sundaram, S. K., Mahavisno, V., Barrette, T. R., Ghosh, D., & Chinnaiyan, A. M. (2005) · Nature Genetics · doi:10.1038/ng1578 · Cited by 166
Self-citation
Pharmacogenomic Biomarkers for Improved Drug Therapy—Recent Progress and Future Developments
Lauschke, V. M., Milani, L. A., & Ingelman‐Sundberg, M. (2017) · The AAPS Journal · doi:10.1208/s12248-017-0161-x · Cited by 166

Authors: Kleer, C. G., Cao, Q., Varambally, S., Shen, R., Ota, I., Tomlins, S. A., Ghosh, D., Sewalt, R. G. A. B., Otte, A. P., Hayes, D. F., Sabel, M. S., Livant, D., Weiss, S. J., Rubin, M. A., & Chinnaiyan, A. M.
Affiliations: Brigham and Women's Hospital (US)
ORCID: Kleer, Celina G.
Cao, Qi
Varambally, Sooryanarayana
Shen, Ronglai
Ota, Ichiro
Tomlins, Scott A.
Hayes, Daniel F.
Sabel, Michael S.
Weiss, Stephen J.
Rubin, Mark A.
Chinnaiyan, Arul M.
Venue: Proceedings of the National Academy of Sciences
Publisher: National Academy of Sciences
Published: 2003-09-19
Volume: 100
Issue: 20
Pages: 11606-11611
ISSN: 0027-8424 (ISSN-L)
1091-6490
DOI: 10.1073/pnas.1933744100
PMC: PMC208805
OpenAlex: W2100365251
Cited by: 1,649
References: 38
Citations by year: 2026: 21 · 2025: 43 · 2024: 53 · 2023: 72 · 2022: 55 · 2021: 67 · 2020: 94 · 2019: 69 · 2018: 83 · 2017: 91 · 2016: 109 · 2015: 109 · 2014: 116 · 2013: 114 · 2012: 108
FWCI: 12.78
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Proceedings of the National Academy of Sciences (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
UvA-DARE (University of Amsterdam) (publishedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
Funders: National Cancer Institute (P50-CA-69568, R01CA097063, R01 CA97063, P50CA069568)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mechanisms of cancer metastasis
Keywords: EZH2, Polycomb group proteins, breast cancer aggressiveness, breast cancer progression, cell invasion, anchorage-independent growth, oncogenic transformation, mammary epithelial cells, SET domain, histone deacetylase activity, transcriptional repression, cellular memory, prognostic factors
MeSH terms: Enhancer of Zeste Homolog 2 Protein, Breast, Breast Neoplasms, Cell Transformation, Neoplastic, DNA-Binding Proteins, Epithelial Cells, Female, Humans, Immunohistochemistry, Proteins, RNA, Messenger, Transcription Factors, Polymerase Chain Reaction, Polycomb Repressive Complex 2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks